Business & Finance

MIV Therapeutics reports buy/4 rating by Investrend affiliate SISM Research

Published in Lab Law Weekly, January 12th, 2007

Ernest C. Schlotter, a senior analyst with Investrend Research Syndicate affiliate SISM Research and a four-star analyst according to StarMine, has reiterated his buy/4 rating and $2.50 12-month target valuation for MIV Therapeutics, Inc. (MIVT) in a Research Note.

MIVT recently announced remarkable results from preclinical studies of two of its novel biocompatible polymer-free drug-eluting stent coating technologies that matched or even outperformed Cordis' and Boston Scientific's drug eluting stents, according to the report.

The independently conducted 4-week porcine study at the Erasmus University Medical Center in the Netherlands compared stents...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2007-01-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry